Aamir Malik has joined Pfizer from McKinsey & Company, where he most recently served as the Managing Partner responsible for the firm’s US operations.
As Executive Vice President and Chief Business Innovation Officer, Mr. Malik will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and CEO, Albert Bourla.
Mr. Malik succeeds John Young, Executive Vice President and Chief Business Officer, who recently announced his intent to retire after a 34-year career at Pfizer.
At Pfizer, Mr. Malik will oversee the company’s strategy, business development, portfolio management, pipeline prioritisation, and formation of new business ventures, as well as the advancement of innovative access partnerships with payers and governments around the world.
“We are delighted to welcome Aamir Malik to our executive leadership team in this important role as we enter the next era of innovation for Pfizer and continue our pursuit of both cutting-edge science and opportunities to reimagine how we do business for the benefit of patients and society,” said Mr Bourla.
“Aamir brings with him 25 years of experience developing innovative growth strategies, guiding mergers and acquisitions, and implementing high-impact programs to improve patients’ lives and transform performance for life science companies. He is the ideal leader to drive these efforts.”
